Q5147 Injection, aflibercept-ayyh, 1 milligrams
Also known as: aflibercept biosimilar, Eylea, VEGF inhibitor, anti-VEGF
Injection of aflibercept-ayyh (Eylea), a biosimilar to aflibercept, administered at 1 milligram per dose.
In Plain Language
eye injection; wet macular degeneration treatment; vision medication
Clinical Context
Used for wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Administered by intravitreal injection monthly or every 8 weeks. Inhibits vascular endothelial growth factor.
RVU Information
CPT Q5147 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q5147?
CPT Q5147 (Injection, aflibercept-ayyh, 1 milligrams) is a Q Codes code. Injection of aflibercept-ayyh (Eylea), a biosimilar to aflibercept, administered at 1 milligram per dose.
Is Q5147 covered by insurance?
Q5147 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Used for wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Administered by intravitreal injection monthly or every 8 weeks. Inhibits vascular endothelial growth factor.
When is CPT Q5147 used?
Used for wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Administered by intravitreal injection monthly or every 8 weeks. Inhibits vascular endothelial growth factor.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.